Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2023

13-06-2023 | Tyrosine Kinase Inhibitors | Original Research Article

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study

Authors: Hélène Babey, Philippe Jamme, Hubert Curcio, Jean Baptiste Assié, Remi Veillon, Hélène Doubre, Maurice Pérol, Florian Guisier, Eric Huchot, Chantal Decroisette, Lionel Falchero, Romain Corre, Alexis Cortot, Christos Chouaïd, Renaud Descourt

Published in: Targeted Oncology | Issue 4/2023

Login to get access

Abstract

Background

MET-targeted tyrosine kinase inhibitors (TKIs) demonstrated efficacy in advanced non-small cell lung cancer (aNSCLC) with MET exon14 skipping mutations (METexon14); yet, data on the management of these patients in clinical practice is sparse.

Objective

The aim of this study was to describe the management of METexon14 aNSCLC patients.

Patients and Methods

This real-life, retrospective study analyzed the management of METexon14 aNSCLC. The primary endpoint was the median overall survival (mOS). Secondary endpoints were to assess investigator–progression-free survival (PFS) and mOS in different subgroups: patients treated with (a) crizotinib, regardless of treatment line; (b) anti-MET TKIs (crizotinib, tepotinib, capmatinib); and (c) immunotherapy.

Results

A total of 118 patients were included between December 2015 and January 1, 2020 in 13 centers. Median age was 73 years, 62.7% were female, 83.9% had adenocarcinoma, 92.4% at stage IV, and 27% had more than three metastatic sites. The majority of the patients (106, 89.8%) received at least one systemic treatment; 73% received at least one anti-MET TKI: crizotinib (68.6%), tepotinib (16%), capmatinib (10%). Only 10% received two anti-MET TKIs in their treatment sequences. With a median follow-up of 16 months (95% CI 13.6–29.7), mOS was 27.1 months (95% CI 18–31.4). There was no significant difference between mOS of patients treated and never treated with crizotinib, 19.7 (95% CI 13.6–29.7) and 28 (95% CI 16.4–NR) months, respectively (p = 0.16); mOS of the TKI cohort and of the TKI-naïve patient cohort were 27.1 (95% CI 18–29.7) and 35.6 (95% CI 8.6–NR) months respectively, with no significant difference (p = 0.7).

Conclusions

In this real-life study, there was no evidence of benefit in mOS with anti-MET TKIs.
Literature
1.
Reungwetwattana T, Liang Y, Zhu V, Ou S-HI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017;103:27–37.CrossRefPubMed
2.
Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer—a systematic review and meta-analysis. Lung Cancer. 2018;123:76–82.CrossRefPubMed
3.
Duplaquet L, Kherrouche Z, Baldacci S, Jamme P, Cortot AB, Copin M-C, et al. The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018;37:3200–15.CrossRefPubMed
4.
Bylicki O, Paleiron N, Assié J-B, Chouaïd C. Targeting the MET-signaling pathway in non-small-cell lung cancer: evidence to date. OncoTargets Ther. 2020;13:5691–706.CrossRef
5.
Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nat Rev Cancer. 2018;18:341–58.CrossRefPubMed
6.
Koch JP, Aebersold DM, Zimmer Y, Medová M. MET targeting: time for a rematch. Oncogene. 2020;39:2845–62.CrossRefPubMed
7.
Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850–9.CrossRefPubMed
8.
9.
Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, et al. Characterization of 298 patients with lung cancer harboring MET Exon 14 skipping alterations. J Thorac Oncol. 2016;11:1493–502.CrossRefPubMed
10.
Drilon AE, Camidge DR, Ou S-HI, Clark JW, Socinski MA, Weiss J, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34(15_suppl):108.CrossRef
11.
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30:1985–91.CrossRefPubMed
12.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, et al. Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations. N Engl J Med. 2020;383:931–43.CrossRefPubMedPubMedCentral
13.
Landi L, Chiari R, Tiseo M, D’Incà F, Dazzi C, Chella A, et al. Crizotinib in MET-DEregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective. Multicenter Two-Arms Trial Clin Cancer. 2019;25:7312–9.
14.
Wolf J, Seto T, Han J-Y, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET Exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383:944–57.CrossRefPubMed
15.
Cortot A, Le X, Smit E, Viteri S, Kato T, Sakai H, et al. Safety of MET tyrosine kinase inhibitors in patients with MET Exon 14 skipping non-small cell lung cancer: a clinical review. Clin Lung Cancer. 2022;23:195–207.CrossRefPubMed
16.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed
17.
18.
Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022;13(14):175.
19.
Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019;133:96–102.CrossRefPubMed
20.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321–8.CrossRefPubMedPubMedCentral
21.
Mayenga M, Assié J-B, Monnet I, Massiani M-A, Tabeze L, Friard S, et al. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: a series of 6 cases. Lung Cancer. 2020;150:21–5.CrossRefPubMed
22.
Kato Y, Yamamoto G, Watanabe Y, Yamane Y, Mizutani H, Kurimoto F, et al. Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. Int J Clin Oncol. 2021;26:1065–72.CrossRefPubMed
23.
Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25.CrossRefPubMed
24.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.CrossRefPubMed
25.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.CrossRefPubMed
26.
Drilon A, Clark JW, Weiss J, Ou S-HI, Camidge DR, Solomon BJ, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020;26:47‑51.
27.
Bittoni M, Yang JC, Shih JY. et a; Real-world insights into patients with advanced NSCLC and MET alterations. Lung Cancer. 2021;159:96–106.CrossRefPubMed
28.
Lee JK, Madison R, Classon A. Characterization of non-small-cell lung cancers with MET Exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns. JCO Precis Oncol. 2021;5:PO.21.00122.PubMedPubMedCentral
29.
Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN. MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis. PLoS ONE. 2014;9: e107677.CrossRefPubMedPubMedCentral
30.
31.
Camidge DR, Otterson GA, Clark JW, Ou S-HI, Weiss J, Ades S, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. J Clin Oncol. 2018;36(15_suppl):9062.CrossRef
32.
Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, et al. MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721–30.CrossRefPubMed
Metadata
Title
Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study
Authors
Hélène Babey
Philippe Jamme
Hubert Curcio
Jean Baptiste Assié
Remi Veillon
Hélène Doubre
Maurice Pérol
Florian Guisier
Eric Huchot
Chantal Decroisette
Lionel Falchero
Romain Corre
Alexis Cortot
Christos Chouaïd
Renaud Descourt
Publication date
13-06-2023
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2023
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-023-00976-4

Other articles of this Issue 4/2023

Targeted Oncology 4/2023 Go to the issue

Original Research Article

Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis

Original Research Article

Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours

Original Research Article

Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case–Control Study

Original Research Article

Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer

Review Article

PARP inhibitors in ovarian cancer

Original Research Article

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits